financetom
Business
financetom
/
Business
/
Porsche stops production of some combustion models early
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Porsche stops production of some combustion models early
Jul 8, 2024 1:48 AM

FRANKFURT (Reuters) - Porsche is sticking to its guns in its transition to electric vehicles, bringing forward the end of production of some internal-combustion models, the carmaker's head of production told magazine Automobilwoche.

Porsche executive board member Albrecht Reimold said that the petrol-powered version of SUV model Macan for non-European markets would be produced no longer than 2026, sooner than initially projected.

"The platform has reached the end of its cycle," said Reimold.

After the production stop the company would focus on electric Macan versions to push Porsche's sustainability agenda, even though EV demand had seen a slump, Reimold was quoted as saying.

"I don't let the success (of the electric Macan) be defined by a single number," the executive was quoted as saying.

Combustion engine versions of Boxster and Cayman sportscars, a model range known as 718, would no longer be produced from some time next year and the company is already focused on electric versions to be launched next year, Reimold added.

Production of petrol-powered versions of 718 and Macan for European markets have already been stopped.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Stellantis Axes First Level 3 Advanced Driver-Assistance Program
Market Chatter: Stellantis Axes First Level 3 Advanced Driver-Assistance Program
Aug 26, 2025
07:55 AM EDT, 08/26/2025 (MT Newswires) -- Stellantis ( STLA ) has axed its first Level 3 advanced driver-assistance program due to high costs, technology issues, and concerns over market viability, Reuters reported Tuesday, citing three sources familiar with the matter. According to Reuters, a Stellantis ( STLA ) spokesperson said the L3 technology that was announced in February has...
MCF Energy Increased Financing To $1.2 Million
MCF Energy Increased Financing To $1.2 Million
Aug 26, 2025
07:55 AM EDT, 08/26/2025 (MT Newswires) -- MCF Energy ( MCFNF ) overnight Monday increased its previously announced non-brokered financing from $500,000 to $1,200,000. A statement noted the Offering will consist of 24 million units at a price of $0.05 per Unit. Each Unit will consist of one common share and one full common share purchase warrant with each warrant...
Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients
Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients
Aug 26, 2025
07:54 AM EDT, 08/26/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday that its investigational cemdisiran monotherapy met the primary and key secondary endpoints in a late-stage trial in adults with generalized myasthenia gravis. The company said Cemdisiran monotherapy showed a 2.3-point placebo-adjusted improvement in MG-ADL total score. Detailed results from the trial will be presented at an...
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
Aug 26, 2025
07:54 AM EDT, 08/26/2025 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Tuesday its investigational therapy MT-601 achieved a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, and 50% showed a complete response. In the phase 1 study, eight out of 12 non-Hodgkin lymphoma patients responded to treatment, including six with complete responses, Marker Therapeutics ( MRKR...
Copyright 2023-2026 - www.financetom.com All Rights Reserved